Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Keeping Track: Early Thanks Given By ImmunoGen, Provention Bio; More PD-1/L1 Combo Approvals

Nov 19 2022

• By Bridget Silverman

Keeping Track Feature image

Related Content

Accelerated Approval Under Review By US FDA: Completing Confirmatory Trials A Focus

Nov 05 2020

Provention Plans Two-Phase Launch Of Tzield, Pricing Drug Higher Than Expected

Nov 18 2022

ImmunoGen Transitions To Commercial Stage With Elahere Launch

Nov 15 2022

Libtayo Gains Approval for First-Line NSCLC With Chemotherapy

Nov 09 2022

Related Companies

ImmunoGen, Inc.

Provention Bio, Inc.

Roche Holding AG

AstraZeneca PLC

Regeneron Pharmaceuticals, Inc.

MacroGenics, Inc.

Eli Lilly and Company

Sanofi

Jazz Pharmaceuticals plc

UCB S.A.

Protalix BioTherapeutics, Inc.

Chiesi

Additional Topics

United States Approvals Drug Review Drug Approval Standards Regulation US FDA Performance Tracker Metabolic Disorders Cancer BioPharmaceutical

More from US FDA Performance Tracker

More from Regulatory Trackers

Twitter feed RSS feed RSS feed

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.